首页> 外文期刊>Alzheimer’s & dementia: the journal of the Alzheimer’s Association >Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease
【24h】

Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease

机译:淀粉样蛋白正电子发射断层显像与18F-氟替莫尔及结构磁共振成像在轻度认知障碍和阿尔茨海默氏病分类中的应用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: To evaluate the contributions of amyloid-positive (Am+) and medial temporal atrophy-positive (MTA+) scans to the diagnostic classification of prodromal and probable Alzheimer's disease (AD). Methods: 18F-flutemetamol-labeled amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) were used to classify 10 young normal, 15 elderly normal, 20 amnestic mild cognitive impairment (aMCI), and 27 AD subjects. MTA+ status was determined using a cut point derived from a previous study, and Am+ status was determined using a conservative and liberal cut point. Results: The rates of MRI scans with positive results among young normal, elderly normal, aMCI, and AD subjects were 0%, 20%, 75%, and 82%, respectively. Using conservative cut points, the rates of Am+ scans for these same groups of subjects were 0%, 7%, 50%, and 93%, respectively, with the aMCI group showing the largest discrepancy between Am+ and MTA+ scans. Among aMCI cases, 80% of Am+ subjects were also MTA+, and 70% of amyloid-negative (Am-) subjects were MTA+. The combination of amyloid PET and MTA data was additive, with an overall correct classification rate for aMCI of 86%, when a liberal cut point (standard uptake value ratio = 1.4) was used for amyloid positivity. Interpretation: 18F-flutemetamol PET and structural MRI provided additive information in the diagnostic classification of aMCI subjects, suggesting an amyloid-independent neurodegenerative component among aMCI subjects in this sample.
机译:目的:评估淀粉样蛋白阳性(Am +)和颞内侧萎缩阳性(MTA +)扫描对前驱性和可能性阿尔茨海默氏病(AD)的诊断分类的贡献。方法:使用18 F-氟他莫尔标记的淀粉样蛋白正电子发射断层扫描(PET)和磁共振成像(MRI)对10名年轻正常,15名老年正常,20名轻度轻度认知障碍(aMCI)和27名AD受试者进行分类。使用先前研究得出的分界点确定MTA +地位,并使用保守和宽松的分界点确定Am +地位。结果:年轻正常,老年正常,aMCI和AD受试者的MRI扫描阳性率分别为0%,20%,75%和82%。使用保守的切点,这些相同组受试者的Am +扫描率分别为0%,7%,50%和93%,其中aMCI组显示Am +和MTA +扫描之间的最大差异。在aMCI病例中,80%的Am +受试者也是MTA +,而70%的淀粉样蛋白阴性(Am-)受试者也是MTA +。淀粉样蛋白PET和MTA数据的组合是累加的,当使用自由切割点(标准摄取值比= 1.4)进行淀粉样蛋白阳性时,aMCI的总体正确分类率为86%。解释:18 F-氟美他莫PET和结构MRI在aMCI受试者的诊断分类中提供了附加信息,表明该样品中aMCI受试者中淀粉样蛋白依赖性神经退行性成分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号